From March 12-14, 2026, the BIO CHINA 2026 International Convention, hosted by Enmore Bio, took place in Suzhou. The annual event, one of the most influential gatherings in China's biopharmaceutical industry, drew over 30,000 attendees, bringing together global biopharma companies, investors, research institutions, and industry experts for in-depth discussions on innovative drug development, business development transactions, and commercialization, exploring industry trends and collaboration opportunities.
Dr. Chao Tu, Co-Founder, President and CEO of Biomissile, Speaks at BIO CHINA 2026
Dr. Chao Tu participated in a panel discussion titled " Insights into Bispecific/Multispecific Antibody Innovation and Strategic Collaboration from a BD Transaction Perspective." During the session, Dr. Tu shared the company's strategic perspectives and provided insights into emerging innovation trends in the bispecific and multispecific antibody field. He noted that this segment, as a key pillar of the biopharmaceutical industry, is entering a critical growth phase in which industrial collaboration and strategic BD execution are essential to translate scientific innovation into clinical and commercial success. Dr. Tu emphasized that Biomissile will continue to pursue global partnerships with an open and collaborative approach, working alongside industry peers to drive the development and commercialization of bispecific and multispecific antibody therapeutics.
Biomissile Wins “BIOCHINA 2025 Most Innovative Company” Award
At the convention's award ceremony, Biomissile was honored with the “BIOCHINA 2025 Most Innovative Company” Award, recognizing its leadership in fully human nanobody platforms, bispecific and multispecific antibody platforms, and next-generation immune cell engager technologies. This distinction celebrates companies that demonstrate exceptional innovation capabilities and achieve breakthrough technological advancements in the biopharmaceutical field.
About Biomissile Pharmaceuticals
Biomissile Pharmaceuticals is a clinical-stage biotech company developing fully human domain antibody (UDABTM)-based multi-specific antibodies (UDAB-MTM) for solid tumors, autoimmune diseases, and infectious diseases. Leveraging these proprietary platform technologies, we have developed our UDAB-M Immune Cell Engager (ICE) platform and built a highly differentiated pipeline that selectively activates both NK and T cells, effectively targeting cold tumors, including TAA-low and ADC-resistant solid tumors. In addition to oncology, UDAB-M molecules have been successfully expanded into autoimmune diseases, where they have demonstrated best-in-class potential for B cell depletion and multi-pathway immune blockade.
Link to the news in Chinese: